Literature DB >> 2545346

Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.

A A Hindenburg1, J E Gervasoni, S Krishna, V J Stewart, M Rosado, J Lutzky, K Bhalla, M A Baker, R N Taub.   

Abstract

Anthracycline-sensitive (HL-60) and -resistant (HL-60/AR) cells, which do not overexpress the P-glycoprotein, each transport and distribute daunorubicin (DNR) into distinct intracellular locations, as visualized by digitized video fluorescence microscopy. At pH 7.4, the fluorescence of DNR in HL-60 cells appears distributed diffusely in both the nucleus and cytoplasm. In contrast, HL-60/AR cells show much less fluorescence in the nucleus and cytoplasm; most of the fluorescence localizes first to the Golgi apparatus and is then gradually shifted to the lysosomes and/or mitochondria. In pharmacokinetic studies, HL-60/AR cells exposed to different extracellular concentrations of [14C]DNR consistently accumulated less radioactive drug than the parent HL-60 cells. Incubation of HL-60/AR cells with sodium azide and deoxyglucose blocked the efflux of [14C]DNR and also prevented the shift of DNR fluorescence from the Golgi apparatus to the lysosomes/mitochondria. The efflux and the intracellular shift of DNR could also be inhibited by lowering the temperature to 18 degrees C, which stops endosomal membrane fusion. When DNR was allowed to accumulate in HL-60 or HL-60/AR cells at pH 5 there was an increase in the proportion of drug fluorescence in the membranes of both HL-60 and HL-60/AR cells; a decrease in the amount of drug retained by HL-60, but not by HL-60/AR cells; and a decrease in the cytostatic effects of DNR on both HL-60 and HL-60/AR cells. These data suggest that DNR resistance is associated with a failure of DNR to pass through membranes and to bind to cytoplasmic and nuclear structures. Instead, most of the drug is taken up by the Golgi apparatus from which it is then shifted to the lysosomes or to mitochondria, or out of the cell.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545346

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.

Authors:  N Baldini; K Scotlandi; M Serra; K Kusuzaki; T Shikita; M C Manara; D Maurici; M Campanacci
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Intracellular distribution of anthracyclines in drug resistant cells.

Authors:  G Arancia; A Calcabrini; S Meschini; A Molinari
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP.

Authors:  M A Izquierdo; G L Scheffer; A B Schroeijers; M C de Jong; R J Scheper
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

4.  An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.

Authors:  Yun Mai; J Jessica Yu; Boris Bartholdy; Zijun Y Xu-Monette; Esther E Knapp; Fei Yuan; Hongshan Chen; B Belinda Ding; Zhihua Yao; Bhaskar Das; Yiyu Zou; Ken He Young; Samir Parekh; B Hilda Ye
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 5.  A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Authors:  Kenta Masui; Beatrice Gini; Jill Wykosky; Ciro Zanca; Paul S Mischel; Frank B Furnari; Webster K Cavenee
Journal:  Carcinogenesis       Date:  2013-03-01       Impact factor: 4.944

6.  Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.

Authors:  Zahia Ouar; Marcelle Bens; Caroline Vignes; Marc Paulais; Claudine Pringel; Jocelyne Fleury; Francçoise Cluzeaud; Roger Lacave; Alain Vandewalle
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

7.  The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro.

Authors:  Y Takemura; H Kobayashi; H Miyachi; K Hayashi; S Sekiguchi; T Ohnuma
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Internalization of an intact doxorubicin immunoconjugate.

Authors:  L B Shih; D M Goldenberg; H Xuan; H W Lu; M J Mattes; T C Hall
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

Review 9.  Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug.

Authors:  M S Center
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects.

Authors:  H Kobayashi; Y Takemura; T Ohnuma
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.